ArticleAmerican journal of translational research2025
Extratumoral signs on mammography as a novel prognostic indicator for breast cancer: evidence from malignant nonspiculate and noncalcified masses.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the prognostic significance of extratumoral structural abnormalities associated with malignant nonspiculate and noncalcified masses (NSNCMs) detected on mammography.
methodsData from 354 breast cancer patients with mammographically detected NSNCMs between December 2017 and December 2018 were retrospectively analyzed. Cox regression analysis was performed to assess the impact of mammographic findings, particularly extratumoral structural abnormalities such as parenchymal and trabecular signs, on progression-free survival (PFS). Additionally, Kaplan-Meier survival curves were used for risk stratification.
resultsThe median follow-up period was 74 months (range: 10-83 months). Disease progression occurred in 122 patients (34.5%). Cox regression analysis revealed that among the mammographic features, the extratumoral contraction sign [hazard ratio (HR) = 2.56, 95% confidence interval (CI): 1.60-4.09, P < 0.001] and the extratumoral parallel sign (HR = 2.71, 95% CI: 1.57-4.70, P < 0.001) were independent predictors of NSNCM progression, demonstrating strong prognostic performance. In contrast, tumor signs did not show significant predictive value. Kaplan-Meier analysis further confirmed that these two extratumoral features effectively stratified the risk of progression in patients with malignant NSNCMs. Additionally, lymph node metastasis (HR = 2.37, 95% CI: 1.64-3.42,
conclusionsSpecific extratumoral structural abnormalities and their subclassifications on mammography are independent prognostic indicators in breast cancer patients with malignant NSNCMs. These findings provide an important basis for personalized treatment strategies in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.